Management of patients with asthma or COPD and cardiovascular disease: risksversusbenefits

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

“…The drugs that are typically used to treat the various CVDs are β-AR blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II type 1 (AT1) receptor antagonists, statins, antiplatelet drugs, calcium channel blockers, and diuretics, regardless of whether the patient also has asthma or COPD. 4,5 β-AR blockers. β-AR blockers are beneficial in treating individuals with acute coronary syndromes and in the secondary prevention of coronary events.…”

“…94 Potential pulmonary benefits for patients with CAD when using drugs to treat CVD Medications that reduce the CV risk may significantly influence the clinical outcome of patients with CAD by lowering the CV component of unfavorable morbidity and mortality. 4 β-AR blockers. Nadolol is an inverse agonist and has shown various positive benefits in asthma, but large-scale studies have not been conducted to corroborate these findings.…”

“…Conversely, some of those used to treat comorbidity may reduce the severity of lung disease. 5 Among the many comorbidities associated with asthma and COPD, cardiovascular disease (CVD) 4 and type 2 diabetes mellitus (T2DM) 6 pose problems for the simultaneous treatment of CAD and comorbidity. This is not a minor problem considering the frequency with which CAD, CVD, and T2DM coexist in the same patient.…”

“…However, it cannot be ruled out that the drugs used to treat comorbidity may have an unfavorable impact on CAD, either through a direct effect on the lungs or through a drug–drug interaction that decreases the therapeutic efficacy of the prescribed treatment for CAD. 4 Besides these negative interferences, there is growing evidence that some drugs used to treat CAD benefit comorbidity. Conversely, some of those used to treat comorbidity may reduce the severity of lung disease.…”

Guest Editors

“…In this ERS Monograph, we have tried to offer the reader a complete overview of the interaction between pulmonary diseases and CVDs, not only from an epidemiological point of view [1], but also from a pathophysiological [2], and more particularly, clinical and therapeutic point of view. Accordingly, after reviewing some basic concepts, the book has been divided into: firstly, each important group of respiratory diseases and their cardiopulmonary implications [3][4][5][6][7][8][9][10][11][12][13][14]; then to the groups of drugs most used in pulmonology and their potential cardiovascular effects [15][16][17][18][19]; and finally, to future diagnostic challenges in this field [20]. Three clinical cases have also been chosen to illustrate different situations taken from real life, in order to delve more fully into the concepts discussed in this book [21][22][23].…”